While estimated 48-month PFS rates for VenO-treated TP53 aberrant CLL were 54.2%, the presence of del(17p), along with high disease burden, were associated with inferior PFS on multivariate analysis [8]. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.